Display options
Cite
Chapelon-Abric C, Sene D, Saadoun D, et al. Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. Arch Cardiovasc Dis. 2017;110(8):456-465doi: 10.1016/j.acvd.2016.12.014.
Chapelon-Abric, C., Sene, D., Saadoun, D., Cluzel, P., Vignaux, O., Costedoat-Chalumeau, N., Piette, J. C., & Cacoub, P. (2017). Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. Archives of cardiovascular diseases, 110(8), 456-465. https://doi.org/10.1016/j.acvd.2016.12.014
Chapelon-Abric, Catherine, et al. "Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors." Archives of cardiovascular diseases vol. 110,8 (2017): 456-465. doi: https://doi.org/10.1016/j.acvd.2016.12.014
Chapelon-Abric C, Sene D, Saadoun D, Cluzel P, Vignaux O, Costedoat-Chalumeau N, Piette JC, Cacoub P. Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. Arch Cardiovasc Dis. 2017 Aug - Sep;110(8):456-465. doi: 10.1016/j.acvd.2016.12.014. Epub 2017 May 26. PMID: 28566197.
Copy Download .nbib Format: NLM
Share it on

Arch Cardiovasc Dis. 2017 Aug - Sep;110(8):456-465. doi: 10.1016/j.acvd.2016.12.014. Epub 2017 May 26.

Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors.

Archives of cardiovascular diseases

Catherine Chapelon-Abric, Damien Sene, David Saadoun, Philippe Cluzel, Olivier Vignaux, Nathalie Costedoat-Chalumeau, Jean-Clarles Piette, Patrice Cacoub

Affiliations

  1. Département de Médecine Interne et d'Immunologie Clinique, CHU Pitié-Salpétrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: [email protected].
  2. Département Médecine Interne, Hôpital Lariboisière, 75475 Paris, France.
  3. Département de Médecine Interne et d'Immunologie Clinique, CHU Pitié-Salpétrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  4. Service de Radiologie, CHU Pitié-Salpétrière, 75013 Paris, France.
  5. Service de Radiologie, Hôpital Cochin, 75014 Paris, France.
  6. Département Médecine Interne, Hôpital Cochin, 75014 Paris, France.
  7. Département Médecine Interne, CHU Pitié-Salpétrière, 75013 Paris, France.
  8. UMR 7211, Inflammation-Immunopathology-Biotherapy Department, Département de Médecine Interne et d'Immunologie Clinique, Sorbonne Universités, UPMC Université Paris, CHU Pitié-Salpétrière, 75005 Paris, France.

PMID: 28566197 DOI: 10.1016/j.acvd.2016.12.014

Abstract

BACKGROUND: Cardiac sarcoidosis (CS) is a severe localization, observed mostly in cardiology departments. Despite appropriate cardiological treatment, CS is a potentially life-threatening condition, and accounts for 13-85% of sarcoidosis-related deaths.

AIMS: This retrospective study aimed to give an overview of CS in a non-cardiac unit, to analyse the effect of first-line immunosuppressive treatment on outcome and survival and to evaluate factors associated with relapses.

METHODS: From 534 cases of sarcoidosis, we selected 59 patients with CS according to "2006 international criteria". We performed an in-depth analysis regarding symptoms, physical signs and cardiac investigation results. Patients were followed for a median period of 60 months.

RESULTS: The median age at cardiac signs was 42 years. Echocardiography abnormalities, isotopic defects and abnormal magnetic resonance imaging findings were observed in 81%, 84% and 92% of patients, respectively. First-line treatment included steroids alone in 24 patients and steroids plus immunosuppressive therapy in 35 patients. Forty-seven (80%) patients recovered; 12 stabilized or worsened. The recovery rate was 75% in the steroids alone group versus 83% in the steroids plus immunosuppressive therapy group. Five (9%) patients died during follow-up, with two deaths attributed to CS. The overall 1- and 5-year survival rates were 98% and 92%, respectively.

CONCLUSION: Our series of patients with CS who received steroids alone or combined with immunosuppressive therapy had a good prognosis, with an overall 5-year survival rate of 92%. The recovery rate was 85%, with no significant difference between patients treated with steroids alone or plus immunosuppressive therapy.

Copyright © 2017. Published by Elsevier Masson SAS.

Keywords: Cardiac sarcoidosis; Corticoïdes; Cyclophosphamide; Methotrexate; Méthotrexate; Rechute taux de guérison; Relapse; Sarcoïdose cardiaque; Steroids; Survival rate

Publication Types